Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
99mTc-FAPI-YQ3: sourced facts only. name: "In conclusion, 99mTc-FAPI-YQ3 was a promising radiotracer for FAP-targeted cancer diagnosis, shedding light on substantially advancing SPECT molecular imaging." [PMID:40085735]; target: "In conclusion, 99mTc-FAPI-YQ3 was a promising radiotracer for FAP-targeted cancer diagnosis, shedding light on substantially advancing SPECT molecular imaging." [PMID:40085735]; developer: "State Key Laboratory of Natural Medicines, Department of Biomedical Engineering, School of Engineering, China Pharmaceutical University, Nanjing 211198, China." [PMID:40085735]; modality: "In conclusion, 99mTc-FAPI-YQ3 was a promising radiotracer for FAP-targeted cancer diagnosis, shedding light on substantially advancing SPECT molecular imaging." [PMID:40085735]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 99mTc-FAPI-YQ3.